|
| 37632469 | Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. | Circulation | 2024 |
| 37713477 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. | Diabetes Care | 2024 |
| 37290700 | Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. | Am Heart J | 2023 |
| 36335918 | Survival After Invasive or Conservative Management of Stable Coronary Disease. | Circulation | 2023 |
| 36270493 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. | Int J Cardiol | 2023 |
| 37702079 | Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5â¿¿Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial. | J Am Heart Assoc | 2023 |
| 36566304 | External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. | J Thromb Thrombolysis | 2023 |
| 36697143 | Temporal Trends in Gender of Principal Investigators and Patients in Cardiovascular Clinical Trials. | J Am Coll Cardiol | 2023 |
| 37116789 | Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. | Can J Cardiol | 2023 |
| 35196863 | Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. | Circ Cardiovasc Interv | 2022 |
| 35775415 | Trials and Tribulations of Randomized Clinical Trials. | Circulation | 2022 |
| 35770629 | Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. | Circulation | 2022 |
| 35710660 | A Retrospective Analysis of Medical Student Performance Evaluations, 2014-2020: Recommend with Reservations. | Journal of General Internal Medicine | 2022 |
| 36302586 | Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. | J Am Coll Cardiol | 2022 |
| 36153281 | Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. | J Clin Lipidol | 2022 |
| 35488865 | Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. | Eur Heart J Cardiovasc Pharmacother | 2022 |
| 36328873 | Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab. | J Am Coll Cardiol | 2022 |
| 35861800 | Response by Cavender et al to Letter Regarding Article, "Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX". | Circ Cardiovasc Interv | 2022 |
| 35411785 | Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. | Circ Cardiovasc Interv | 2022 |
| 35545204 | Iterative approaches to the use of electronic health records data for large pragmatic studies. | Contemp Clin Trials | 2022 |
| 36993910 | Sociodemographic determinants of oral anticoagulant prescription in patients with atrial fibrillations: findings from the PINNACLE registry using machine learning. | Heart Rhythm O2 | 2022 |
| 35321823 | Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI. | Am Heart J | 2022 |
| 35296402 | Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. | Am J Med | 2022 |
| 34915723 | Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. | Circ Cardiovasc Interv | 2022 |
| 35232819 | Changing the Trajectory of Heart Failure and Kidney Disease: A Call for Action. | Clinical journal of the American Society of Nephrology : CJASN | 2022 |
| 35213721 | Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) | European Heart Journal: Acute Cardiovascular Care | 2022 |
| 35166796 | Diagnosis and Treatment of Acute Coronary Syndromes: A Review. | JAMA | 2022 |
| 35091313 | Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. | Thromb Res | 2022 |
| 34814698 | Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. | Circ Cardiovasc Interv | 2021 |
| 34297072 | Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. | JAMA Netw Open | 2021 |
| 34297072 | Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. | JAMA Netw Open | 2021 |
| 33587663 | Temporal Trends in the Proportion of Women Physician Speakers at Major Cardiovascular Conferences. | Circulation | 2021 |
| 33534976 | Management of Antithrombotic Therapy after Acute Coronary Syndromes. | N Engl J Med | 2021 |
| 34268712 | Gender Disparities in Cardiology-Related COVID-19 Publications. | Cardiol Ther | 2021 |
| 33999548 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. | N Engl J Med | 2021 |
| 33840208 | Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement. | Circulation | 2021 |
| 33994057 | 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. | J Am Coll Cardiol | 2021 |
| 33939527 | A Return to Normal Is Not Good Enough. | Circulation | 2021 |
| 33985685 | Global Prevalence and Impact of Hostility, Discrimination, and Harassment in the Cardiology Workplace. | J Am Coll Cardiol | 2021 |
| 33506685 | Taking a Stand Against Air Pollution-The Impact on Cardiovascular Disease: A Joint Opinion From the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. | Circulation | 2021 |
| 34029138 | The Need to Expand the Framework of Environmental Determinants of Cardiovascular Health From Climate Change to Planetary Health: Trial by Wildfire. | Circulation | 2021 |
| 33598388 | Taking a Stand Against Air Pollution - The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. | Global Heart | 2021 |
| 33646828 | COVID-19 at 1 Year: American Heart Association Presidents Reflect on the Pandemic. | Circulation | 2021 |
| 33020988 | The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review. | Journal of Internal Medicine | 2021 |
| 33270604 | Generating evidence for therapeutic effects: the need for well-conducted randomized trials. | J Clin Invest | 2021 |
| 33051646 | Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. | Eur Heart J | 2020 |
| 32381160 | Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. | J Am Coll Cardiol | 2020 |
| 32380228 | Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. | Can J Cardiol | 2020 |
| 32380058 | Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. | Ann Thorac Surg | 2020 |
| 32380033 | Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. | J Am Coll Cardiol | 2020 |